Prednisolone and rituximab
ApprovedMonoclonal antibody
Prednisolone and rituximab is one of 15 small molecule programs targeting ANCA-Associated Vasculitis. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
18 competitors in ANCA-Associated Vasculitis
#DrugCompanyPhaseTrials
1Tavneos
AmgenApproved
Rituxan
RochePhase 3
Glucocorticoids
NovartisApproved
Actos
TakedaPhase 3
Telitacicept
VVor Biopharma
Approved
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Imuran
LLegacy Health System
Phase 3
Rayos
RRoxane Laboratories
Phase 3
Flagyl
DDePuy Orthopaedics
Phase 3
PCV13
SanofiPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
ANCA-Associated Vasculitis1 trial
Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis
Recruiting·—·Phase 4·NCT06611696·160 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Prednisolone and rituximab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Approved[1]
- Company
- CChiba University